Radiopharmaceuticals: all 1,299 studies that test it

Page 10 of 13. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.

• Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate CancerWithdrawnNCT03581500Phase 2
• Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab TreatmentTerminatedNCT03573986Phase 1
• A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma SubjectsStatus unknownNCT03561259Phase 2
• 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia SyndromesStatus unknownNCT03555292Phase 2
• 18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant PatientsTerminatedNCT03546556Early Phase 1
• 99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 CharacterizationCompletedNCT03546478Early Phase 1
• Phase 1 Test-retest Evaluation of [18F]MNI-958 PETCompletedNCT03545789Phase 1
• 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing MastectomyCompletedNCT03542695Early Phase 1
• [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy VolunteersTerminatedNCT03539731Phase 1
• A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate CancerStatus unknownNCT03516045Phase 1/2
• Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After SurgeryCompletedNCT03515577Phase 2
• A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine NeoplasmsStatus unknownNCT03511768Phase 1/2
• Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the BrainCompletedNCT03510572Early Phase 1
• First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express MesothelinCompletedNCT03507452Phase 1
• Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.CompletedNCT03497377Phase 1
• Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation TherapyCompletedNCT03493789Phase 1
• 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate CancerTerminatedNCT03490838Phase 1
• MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT03489525Phase 1
• Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 1
• Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT03478358Phase 1
• Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate CancerActive, not recruitingNCT03471650Phase 2
• Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NETTerminatedNCT03466216Phase 1
• Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal TherapyStatus unknownNCT03458559Phase 3
• Investigation of PSMA PET/CT as an Imaging Biomarker in Solid TumorsCompletedNCT03453528Not applicable
• Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and LymphomaStatus unknownNCT03436342Early Phase 1
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
• 11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human SubjectsCompletedNCT03424525Phase 1
• Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and ChemotherapyActive, not recruitingNCT03422731Early Phase 1
• FAZA PET/MRI SarcomaActive, not recruitingNCT03418818Not applicable
• 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate CancerStatus unknownNCT03403595Phase 1
• The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal PatientsStatus unknownNCT03385148Early Phase 1
• Ga-68-PSMA-11 in High-risk Prostate CancerCompletedNCT03362359Phase 1/2
• Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.Status unknownNCT03349463Phase 4
• 68Ga-NOTA-RM26 PET/CT in Breast Tumor PatientsStatus unknownNCT03347864Early Phase 1
• Gallium 68 Pentixafor in Patients With Neuroendocrine TumorsActive, not recruitingNCT03335670Early Phase 1
• Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASHTerminatedNCT03332940Phase 1
• Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer PatientsTerminatedNCT03331601Phase 2
• 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT03308682Phase 1
• uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor AggressivenessStatus unknownNCT03307460Phase 2
• Glutamine PET Imaging Colorectal CancerTerminatedNCT03275974Phase 1
• Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTCCompletedNCT03246659Phase 1
• [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer ImagingCompletedNCT03242993Phase 1
• Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.TerminatedNCT03232632Early Phase 1
• Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node BiopsyStatus unknownNCT03199560Phase 4
• Use of PET/MR Imaging in Chronic PainCompletedNCT03195270Phase 1
• Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CTCompletedNCT03183570Early Phase 1
• 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerActive, not recruitingNCT03181867Phase 2
• 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate CancerActive, not recruitingNCT03173924Phase 2
• 68Ga-NOTA-RM26 PET/CT in Prostate Cancer PatientsStatus unknownNCT03164837Phase 1
• Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical CancerTerminatedNCT03129776Phase 1
• PET/MRI Evaluation of Cardiac AmyloidCompletedNCT03119558Early Phase 1
• Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as RadioimmunotherapyTerminatedNCT03118349Phase 1
• A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human BrainCompletedNCT03089918Phase 1
• A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739CompletedNCT03088644Phase 1
• Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast CancerActive, not recruitingNCT03083288Phase 1
• Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal CancerCompletedNCT03073395Phase 1
• 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung CancerStatus unknownNCT03065764Phase 2
• Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 TherapyCompletedNCT03062254Phase 2
• Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography StudyWithdrawnNCT03057938Phase 2
• A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid TumorsWithdrawnNCT03057509Phase 1
• Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82CompletedNCT03048097Early Phase 1
• Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine TumorsActive, not recruitingNCT03044977Early Phase 1
• 18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyCompletedNCT03042416Phase 3
• Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or BiopsyCompletedNCT03039413Early Phase 1
• Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)CompletedNCT03030885Phase 1
• 68Ga-PSMA PET/CT in Prostate CancerCompletedNCT03001869Phase 3
• 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine TumorsTerminatedNCT03001349Early Phase 1
• A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need SurgeryCompletedNCT02980679Phase 3
• Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck CancerCompletedNCT02965001Phase 2
• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
• Biodistribution/Reproducibility Ga-68 PSMA-HBED-CCCompletedNCT02952469Early Phase 1
• 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically TreatedCompletedNCT02920229Not applicable
• 18F-FLT PET Imaging in Patients With Advanced MelanomaTerminatedNCT02891616Phase 1
• Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)Status unknownNCT02880943Phase 1/2
• PET Imaging of Ovarian Carcinoma With 18F-FSPGWithdrawnNCT02872519Early Phase 1
• Stress and Rest Myocardial Tomoscintigraphies Using Mono- or Double-isotope Protocol With a Semiconductor CameraCompletedNCT02869126Not applicable
• A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the AnusWithdrawnNCT02857608Phase 2
• The Role of C-11 Choline PET in Patients With Prostate CancerCompletedNCT02852122Not applicable
• 18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN StudyCompletedNCT02850146Phase 1
• The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate CancerCompletedNCT02840552Phase 3
• Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041CompletedNCT02826382Early Phase 1
• Phosphate in Blood Pressure RegulationCompletedNCT02822131Not applicable
• Dual SSTR2 and Integrin αvβ3 Targeting PET/CT ImagingStatus unknownNCT02817945Early Phase 1
• Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorCompletedNCT02814669Phase 1
• Cerebral Amyloid Imaging Using Florbetapir (AV-45)CompletedNCT02813434Phase 3
• 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate CancerTerminatedNCT02809690Phase 1
• Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT TracersCompletedNCT02802969Phase 2
• A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell LymphomaWithdrawnNCT02776891Phase 2
• Pembrolizumab-PET ImagingCompletedNCT02760225Not applicable
• [18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and SciaticaCompletedNCT02753101Early Phase 1
• Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer PatientsStatus unknownNCT02749019Phase 1
• 68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer PatientsStatus unknownNCT02747290Early Phase 1
• 99mTc-3PRGD2 SPECT/CT in Esophagus Cancer PatientsCompletedNCT02744729Early Phase 1
• 99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis PatientsCompletedNCT02723760Early Phase 1
• C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate CancerCompletedNCT02715583Early Phase 1
• Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast CancerTerminatedNCT02708511Phase 1
• F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)WithdrawnNCT02707978Phase 2
• 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung CancerActive, not recruitingNCT02701699Not applicable
• A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the LiverStatus unknownNCT02693067Phase 1
• Integrated 18F-labelled PSMA ProjectStatus unknownNCT02691169Early Phase 1

← Radiopharmaceuticals overview